SENXUAN(BJ:830946) Xin Jing Bao·2025-11-13 10:20Core Insights - Jiangsu Senxuan Pharmaceutical Co., Ltd. is a leading enterprise in the domestic specialty raw materials pharmaceutical sector and was among the first to be listed on the Beijing Stock Exchange [1][7] - The company emphasizes innovation and R&D as its core strategy, maintaining a high level of investment in research and development [3][4] R&D and Innovation - Senxuan Pharmaceutical has established multiple provincial R&D platforms and has capabilities across various stages of drug development, achieving international advanced levels in several product technical indicators [3] - The company invested nearly 20 million yuan in R&D in the first three quarters, representing about 4.85% of its revenue, and has made breakthroughs in green synthesis processes and other areas [3][4] Financial Performance - In the first three quarters, the company achieved revenue of 411 million yuan, a year-on-year increase of 5.9%, and a net profit of 104 million yuan, up 13.45% year-on-year [5] - The company has maintained a stable cash dividend policy, distributing approximately 60 million yuan to shareholders, reflecting confidence in future growth [5] Market Position and Growth Strategy - The company is focused on consolidating its market position and creating new growth points through overseas market expansion and new product sales [5] - Future strategies include continuous R&D investment, optimizing production processes, and exploring strategic investments in pet medicine and medical aesthetics [6] Impact of Listing on the Beijing Stock Exchange - Listing on the Beijing Stock Exchange has significantly enhanced the company's brand credibility and industry influence, improving its reputation among clients and attracting high-quality management talent [7] - The funds raised from the IPO are being used to advance projects that will alleviate capacity bottlenecks and support larger market orders [7][8]